Page 36 - Read Online
P. 36

Page 18 of 18                 Padoan et al. Vessel Plus 2021;5:41  https://dx.doi.org/10.20517/2574-1209.2021.41

               100.      Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of Eosinophilic Granulomatosis with
                    Polyangiitis (EGPA). Ann Allergy Asthma Immunol 2021:S1081-1206(21)00097.  DOI  PubMed
               101.      Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with
                    polyangiitis. J Allergy Clin Immunol Pract 2021;9:1186-93.  DOI  PubMed
               102.      Padoan R, Chieco Bianchi F, Marchi MR, et al. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in
                    eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 2020;8:3225-7.e2.  DOI  PubMed
               103.      Kita H. Eosinophils: Multifaceted biological properties and roles in health and disease. Immunol Rev 2011;242:161-77.  DOI
                    PubMed  PMC
               104.      Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum
                    eosinophilia. J Allergy Clin Immunol 2013;132:1086-96.  DOI  PubMed  PMC
               105.      Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for
                    the treatment of severe asthma: a systematic review. Eur Respir J 2018;52:1801393.  DOI  PubMed  PMC
               106.      Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a
                    randomized trial. Ann Intern Med 2011;154:573-82.  DOI  PubMed
               107.      Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy
                    Clin Immunol 2020;146:595-605.  DOI  PubMed
               108.      Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of
                    omalizumab clinical trials. Ann Allergy Asthma Immunol 2017;118:500-4.  DOI  PubMed
               109.      Caruso C, Gencarelli G, Gaeta F, et al. Efficacy of omalizumab treatment in a man with occupational asthma and eosinophilic
                    granulomatosis with polyangioitis. Ann Allergy Asthma Immunol 2018;120:209-11.  DOI  PubMed
               110.      Aguirre-Valencia D, Posso-Osorio I, Bravo JC, et al. Sequential rituximab and omalizumab for the treatment of eosinophilic
                    granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol 2017;36:2159-62.  DOI  PubMed
               111.      Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month
                    follow-up study. J Asthma 2016;53:201-6.  DOI  PubMed
               112.      Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic
                    granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 2016;68:2274-82.  DOI  PubMed
               113.      Winchester DE, Jacob A, Murphy T. Omalizumab for Asthma. N Engl J Med 2006;355:1281-2.  DOI  PubMed
               114.      Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008;19:364-6.  DOI
                    PubMed
               115.      Basta F, Mazzuca C, Nucera E, et al. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? Clin Exp
                    Rheumatol 2020;38 Suppl 124:214-20.  PubMed
               116.      Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force
                    recommendations for evaluation and management. Eur J Intern Med 2015;26:545-53.  DOI  PubMed
               117.      Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic
                    literature review. Autoimmun Rev 2021;20:102737.  DOI  PubMed
               118.      Casal Moura M, Berti A, Keogh KA, et al. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
                    Clin Rheumatol 2020;39:1581-90.  DOI  PubMed
               119.      Sattui SE, Lally L. Localized Granulomatous with polyangiitis (GPA): varied clinical presentations and update on treatment. Curr
                    Allergy Asthma Rep 2020;20:56.  DOI  PubMed
               120.      Holme SS, Moen JM, Kilian K, et al. Impact of paranasal sinus surgery in granulomatosis with polyangiitis: a longitudinal computed
                    tomography study. Laryngoscope 2020;130:E460-8.  DOI  PubMed
               121.      Unadkat SN, Pendolino AL, Kwame I, et al. Nasal reconstructive surgery for vasculitis affecting the nose: our two-centre
                    international experience. Eur Arch Otorhinolaryngol 2020;277:3059-66.  DOI  PubMed
               122.      Sahyouni R, Moshtaghi O, Abouzari M, et al. A case series of granulomatosis with polyangiitis primarily diagnosed by otological
                    manifestations. Ann Otol Rhinol Laryngol 2019;128:263-6.  DOI  PubMed
               123.      Srouji IA, Andrews P, Edwards C, et al. General and rhinosinusitis-related quality of life in patients with Wegener’s granulomatosis.
                    Laryngoscope 2006;116:1621-5.  DOI  PubMed
               124.      Cazzador D, Padoan R, Colangeli R, et al. Health-related quality of life in patients with anca-associated vasculitis and sinonasal
                    involvement: a single-center cross-sectional study. J Clin Rheumatol 2020.  DOI  PubMed
   31   32   33   34   35   36   37   38   39   40   41